Pulmonary Squamous Cell Carcinoma Harboring EGFR Exon 19 Mutation Responded Dramatically to EGFR-TKI-A Case Report

貢獻的翻譯標題: 具表皮細胞生長因子接受器突變之肺麟狀細胞癌病患使用上皮細胞生長因子接收器-酪胺酸酶抑制劑呈顯著治療效果:病例報告

研究成果: 雜誌貢獻文章

摘要

表皮細胞生長因子接受器(Epidermal growth factor receptor,簡稱EGFR)的基因突變常見於非小細胞肺癌病患,尤其是從不抽菸、女性和肺腺癌患者。擁有此突變之病患有較好的EGFR酪胺酸酶抑制劑(Tyrosine kinase inhibitor,簡稱TKI)治療效果和預後。我們提出的個案為一個不抽菸女性患有肺麟狀細胞癌併發腦部遠處轉移,卻罕見地擁有EGFR exon 19突變,並對EGFR TKI治療有顯著的療效。此篇病例報告指出EGFR基因突變分析應可實行於肺麟狀細胞癌的病患,尤其是具有亞裔、女性和從不抽菸的特徵者,而且可為此類病人提供使用標靶治療的機會。
原文英語
頁(從 - 到)157-163
頁數7
期刊胸腔醫學
30
發行號3
出版狀態已發佈 - 2015

指紋

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Squamous Cell Carcinoma
Exons
Lung
Mutation
Smoking
erbB-1 Genes
Non-Small Cell Lung Carcinoma
Histology
Adenocarcinoma
History
Neoplasm Metastasis
Brain
Therapeutics

引用此文

@article{ba22231251c441dc8295674fe2f8abe0,
title = "Pulmonary Squamous Cell Carcinoma Harboring EGFR Exon 19 Mutation Responded Dramatically to EGFR-TKI-A Case Report",
abstract = "Epidermal growth factor receptor (EGFR) gene mutations are common in non-small cell lung cancer (NSCLC) patients characterized by female gender, a history of never smoking and an adenocarcinoma histology. These mutations usually predict favorable EGFR-tyrosine kinase inhibitors (TKIs) treatment efficacy and outcome. We report a non-smoking female with synchronous brain metastasis from pulmonary squamous cell carcinoma (SCC), which uncommonly harbored an EGFR exon 19 mutation and dramatically responded to EGFR TKI treatment. This case highlights that EGFR mutational analysis may be performed for pulmonary SCC patients that are East Asian females without a smoking history. The identification of EGFR mutations in pulmonary SCC may provide a treatment option using EGFR-TKIs.",
keywords = "表皮細胞生長因子接受器突變, 上皮細胞生長因素接收器-酪胺酸酶抑制劑, 肺麟狀細胞癌, epidermal growth factor receptor (EGFR) mutation, EGFR tyrosine kinase inhibitor (TKI), pulmonary squamous cell carcinoma",
author = "Kai-Ling Lee and Sey-En Lin and Cheng-Ching Chung and Shih-Hsin Hsiao and Chi-Li Chung",
year = "2015",
language = "English",
volume = "30",
pages = "157--163",
journal = "胸腔醫學",
issn = "1023-9855",
publisher = "臺灣胸腔暨重症加護醫學會",
number = "3",

}

TY - JOUR

T1 - Pulmonary Squamous Cell Carcinoma Harboring EGFR Exon 19 Mutation Responded Dramatically to EGFR-TKI-A Case Report

AU - Lee, Kai-Ling

AU - Lin, Sey-En

AU - Chung, Cheng-Ching

AU - Hsiao, Shih-Hsin

AU - Chung, Chi-Li

PY - 2015

Y1 - 2015

N2 - Epidermal growth factor receptor (EGFR) gene mutations are common in non-small cell lung cancer (NSCLC) patients characterized by female gender, a history of never smoking and an adenocarcinoma histology. These mutations usually predict favorable EGFR-tyrosine kinase inhibitors (TKIs) treatment efficacy and outcome. We report a non-smoking female with synchronous brain metastasis from pulmonary squamous cell carcinoma (SCC), which uncommonly harbored an EGFR exon 19 mutation and dramatically responded to EGFR TKI treatment. This case highlights that EGFR mutational analysis may be performed for pulmonary SCC patients that are East Asian females without a smoking history. The identification of EGFR mutations in pulmonary SCC may provide a treatment option using EGFR-TKIs.

AB - Epidermal growth factor receptor (EGFR) gene mutations are common in non-small cell lung cancer (NSCLC) patients characterized by female gender, a history of never smoking and an adenocarcinoma histology. These mutations usually predict favorable EGFR-tyrosine kinase inhibitors (TKIs) treatment efficacy and outcome. We report a non-smoking female with synchronous brain metastasis from pulmonary squamous cell carcinoma (SCC), which uncommonly harbored an EGFR exon 19 mutation and dramatically responded to EGFR TKI treatment. This case highlights that EGFR mutational analysis may be performed for pulmonary SCC patients that are East Asian females without a smoking history. The identification of EGFR mutations in pulmonary SCC may provide a treatment option using EGFR-TKIs.

KW - 表皮細胞生長因子接受器突變

KW - 上皮細胞生長因素接收器-酪胺酸酶抑制劑

KW - 肺麟狀細胞癌

KW - epidermal growth factor receptor (EGFR) mutation

KW - EGFR tyrosine kinase inhibitor (TKI)

KW - pulmonary squamous cell carcinoma

M3 - Article

VL - 30

SP - 157

EP - 163

JO - 胸腔醫學

JF - 胸腔醫學

SN - 1023-9855

IS - 3

ER -